Infirst Limited holds intellectual property rights for lipid formulations of NSAIDs for human use in the following 27 countries:
Europe
United Kingdom, Germany, France, Spain, Italy, Holland, Denmark, Belgium, Ireland, Sweden, Switzerland, Poland
Americas
Unites States, Canada, Mexico, Brazil
Central Asia, Africa and Middle East
India, Israel, Russia, South Africa
Asia Pacific
China, Hong Kong, Japan, Singapore, South Korea
Australasia
Australia, New Zealand
The company’s aim is to progressively commercialise Flarin in these countries by working with local or regional partners. Interested parties should contact us via enquiries@infirst.co.uk
